Stay updated on Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial
Sign up to get notified when there's something new on the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page.

Latest updates to the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page
- Check6 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3; no visible changes to study details or navigation.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedAdded Revision: v3.4.2 and removed notices for Revision: v3.4.1 and a government funding status notice. These are administrative site updates and do not affect the study details on the page.SummaryDifference0.5%

- Check41 days agoChange DetectedA government funding-related notice about potential delays and current operating status was added, and the page revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check48 days agoChange DetectedThe changes are cosmetic updates including a new 'Show glossary' toggle and minor label/version text adjustments that do not affect study details or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check62 days agoChange DetectedThe page footer now shows Revision: v3.3.4, replacing Revision: v3.3.3.SummaryDifference0.1%

- Check84 days agoChange DetectedFooter now shows Revision: v3.3.3; HHS Vulnerability Disclosure link and older Revision: v3.3.2 have been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page.